Social Security Retirees Get a New Tax Break in 2025. Hereβs How to Plan For It
AI Sentiment
Positive
7/10
as of 12-15-2025 1:32pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 17.6M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 408.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $2.24 | Next Earning Date: | 11-04-2025 |
| Revenue: | $1,437,000 | Revenue Growth: | -22.41% |
| Revenue Growth (this year): | -51.96% | Revenue Growth (next year): | -38.27% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
8/10
See how LGVN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.